
Nucelion, VeGen Bio Partner for CAR-T Therapy
The story in brief
Bharat Biotech's Nucelion Therapeutics has partnered with Hyderabad-based VeGen Bio to manufacture CAR-T therapy VL-2511 for multiple myeloma. The companies plan to advance the treatment to Phase 1/2 clinical trials in India and aim for commercialisation by 2028, pending regulatory approvals. The agreement focuses on manufacturing, not marketing or distribution.